{"id":50378,"date":"2025-12-10T23:37:09","date_gmt":"2025-12-10T15:37:09","guid":{"rendered":"https:\/\/flcube.com\/?p=50378"},"modified":"2025-12-10T23:37:10","modified_gmt":"2025-12-10T15:37:10","slug":"fosun-pharma-licenses-oral-glp-1r-agonist-yp05002-to-pfizer-in-2-1-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50378","title":{"rendered":"Fosun Pharma Licenses Oral GLP\u20111R Agonist YP05002 to Pfizer in $2.1\u202fBillion Deal"},"content":{"rendered":"\n

Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (SHA: 600196<\/a>, HKG: 2196<\/a>) announced that its subsidiary Chongqing Yaopharma Co., Ltd.<\/strong> has granted Pfizer Inc.<\/strong> (NYSE: PFE<\/a>) exclusive global rights to develop, manufacture, and commercialize YP05002<\/strong>, an oral small\u2011molecule GLP\u20111R agonist<\/strong> for metabolic diseases.<\/p>\n\n\n\n

Transaction Structure<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Asset Licensed<\/strong><\/td>YP05002 (oral GLP\u20111R agonist) + backup compounds<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD 150\u202fmillion (non\u2011refundable)<\/td><\/tr>
Milestone Payments<\/strong><\/td>Up to USD 1.935\u202fbillion (development: $485\u202fM; regulatory: $720\u202fM; commercial: $730\u202fM)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered 8\u201112% on global net sales<\/td><\/tr>
Territory<\/strong><\/td>Worldwide exclusive<\/td><\/tr>
Yao Pharma Role<\/strong><\/td>Complete ongoing Phase\u202fI in Australia; transfer CMC package to Pfizer by Q3\u202f2026<\/td><\/tr>
Pfizer Role<\/strong><\/td>Lead global Phase\u202fII\/III, manufacturing scale\u2011up, and commercialization<\/td><\/tr>
Effective Date<\/strong><\/td>09\u202fDec\u202f2025 (pending antitrust clearance)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Competitive Position<\/h2>\n\n\n\n
Attribute<\/th>YP05002<\/th>Key Competitors<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Oral small\u2011molecule GLP\u20111R agonist<\/td>Injectable semaglutide (Novo), tirzepatide (Lilly); oral semaglutide (Rybelsus)<\/td><\/tr>
Indications<\/strong><\/td>Chronic weight management, Type\u202f2 Diabetes, MASH<\/td>Obesity, T2D (Pfizer\u2019s discontinued lotiglipron targeted same space)<\/td><\/tr>
Phase I Status<\/strong><\/td>Ongoing in Australia (healthy volunteers + T2D patients)<\/td>Phase\u202fI data expected Q3\u202f2026<\/td><\/tr>
Differentiation<\/strong><\/td>Small\u2011molecule (vs peptide) may enable lower cost<\/strong>, improved GI tolerability<\/strong>, and easier combo formulations<\/strong><\/td><\/td><\/tr>
Peak Sales Forecast<\/strong><\/td>$3.5\u20115.0\u202fbillion<\/strong> (global, 2032) if approved<\/td>Oral GLP\u20111 market projected to exceed $25\u202fbillion<\/strong> by 2030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Strategic Implications<\/h2>\n\n\n\n